Pfizer and UK manufacturing partner, Flynn Pharma, have won an appeal against a record £90 million ($120 million) fine levied against them by the UK’s competition authority over price gouging allegations.
In the original lawsuit in 2016, the the Competition and Markets Authority (CMA) alleged that two drug companies had taken advantage of the fact that Epanutin, an anti-epilepsy drug, had lost patent protection and rebranded it and charged a higher price. The UK's National Health Service was charged about £2 million for the drug in 2012 and £50 million for the product in 2013.
However, according to the tribunal verdict, the the Competition and Markets Authority (CMA) used flawed analysis to evaluate whether the price rise was excessive, not making suitable comparisons to other drugs or considering the economic value of the products.
Read the Telegraph coverage